Cases
Experience: Representative Matters: Represented Huadong Medicine, a Chinese publicly traded pharmaceutical company in signing a $300 million license, development
commercialization agreement with Immunogen for the further development
commercialization of mirvetuximab soravtansine (IMGN853) in mainl
China, Hong Kong, Macau,
Taiwan.
Represented Huadong Medicine, a Chinese publicly traded pharmaceutical company in signing a $200 million license, development
commercialization agreement with Provention Bio to develop
commercialize PRV-3279, a DART (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B
CD79B, in Greater China.
Represented Tiancheng Investment Management in the $370 million sale of 25 blood plasma collection centers owned by its UK-based portfolio company, Bio Products Laboratory to Grifols. S.A.
Represented Biotest AG, a German publicly traded biotechnology company in signing $573 million global license, development
commercialization agreement with Abbott Laboratories for the further development
commercialization of a novel anti-CD4 antibody for the treatment of Rheumatoid Arthritis (RA)
psoriasis.
Represented Biotest AG in connection with its $286,000,000 sale of its U.S. blood plasma collection business to Grifols S.A. through a competitive auction process
including significant CFIUS
antitrust counseling.
Represented Biotest AG in connection with the carve-out sale of its plasma therapy business to ADMA Biologics, Inc.
in connection with the related commercial agreements between the companies concerning ongoing plasma supply.
Represented Biotest AG in connection with an exclusive licensing transaction with ADMA Biologics with respect to ADMA's Respiratory Syncytial Virus assay process.
Represented China Gr
Pharma Co., Ltd., a subsidiary of China Gr
Enterprises in connection with a $127 million licensing transaction with a U.S. biotechnology company for the development
commercialization of a drug product in China.
Represented Grunenthal GmbH in connection with a $400 million licensing
commercialization transaction to obtain rights to commercialize in the European Union patent technology rights
products developed by a U.S. biotechnology company.
Represents aap Implantate AG, a German public medical device company that manufactures
distributes globally trauma products for orthopedics in connection with aap's commercial distribution
related agreements
corporate matters, transactions
litigation.
Represented PRA Health Sciences, a global clinical research organization in connection with the creation of a joint venture in Japan with Takeda Pharmaceuticals for the provision of clinical development services to Takeda.
Represented PRA Health Sciences, a global clinical research organization in connection with the creation of a joint venture in China with WuXi AppTech to provide clinical research services
in connection with merger
acquisition activity in China.
Represented a Chinese private equity investment fund in connection with a $300 million acquisition of a U.S. life sciences company, including through a lengthy CFIUS approval process.
Represented VcanBio Technologies, a Chinese publicly traded pharmaceutical company in connection with a $285 million acquisition of a U.S. gene technology
engineering company, including through a lengthy CFIUS approval process.
Represents a global hospitality company in connection with the expansion of its time share business in China, Japan
other countries.
Represents U.S. technology device manufacturer in connection with a venture capital investment in a Chinese manufacturer
a long-term manufacturing, supply
distribution relationship.
Represents Seegene, Inc., a Korean public company
producer of PCR diagnostic testing technology
related devices in connection with joint ventures in Mexico
France
in connection with its strategic distribution
sale agreements as well in connection with market entry
expansion of its business in the U.S.
other countries.
Represents U.S.-based pharmaceutical corporation in connection with all of its corporate matters including the in-licensing of innovative patented technology used in connection with alliances
procurement of new product development technology platforms.
Represents Dart Neuroscience in connection with its strategic licensing
monetization of compounds for the development of neuro disease-related drugs
other strategic transactions.
Represented Chinese biotech company providing antibody discovery
engineering platform services in connection with a research
commercialization relationship for the discovery
commercialization of various antibodies directed against specific target epitopes identified by the commercial partner.
Represented a Chinese biotechnology company in connection with its alliances
other corporate transactions in the U.S.
globally.
Represented U.S. biotechnology company in the licensing of its compounds to an India-based pharmaceutical company for the development
commercialization of drug products in India.
Represented Cantex Pharmaceuticals in connection with its strategic supply contracts for drug product ingredients.
Represents U.S.-based manufacturer of multiple monitoring devices in connection with its international distribution relationships
in connection with related counseling concerning export requirements.
Represented The Weather Company (f/k/a global media
technology company The Weather Channel) as global counsel in connection with the global expansion of its business
product offerings across its platform, including counseling on the international organization of its businesses, joint ventures in China
, partnering deals with major online providers
h
set manufacturers, alliances, FCPA compliance
regulatory compliance.
Represents Neusoft Corporation, a Chinese public company
the largest software development
information technology outsourcing company in China,
its affiliates in connection with various cross-border transactions
joint ventures involving the sharing
development of complex technology platforms
related products, venture capital financings
commercial relationships
in connection with FCPA compliance
general corporate matters.
Represented a Chinese publicly traded environmental engineering company in connection with its first M&A transaction in the U.S.
Represents a large Chinese LED lighting manufacturer in connection with its expansion into the United States.
Represents LINE Corporation, a Korean online texting
voice communications company with over 500 million subscribers globally.
Represented Dutch manufacturer of complex FDA-approved bottling
food processing equipment.
Represent Genesco Inc., a NYSE-traded retailer in connection with its U.S.
foreign operations including contract negotiations
corporate counseling.
Represented U.S. specialty architectural engineering firm in connection with the formation of a joint venture in the U.A.E. with respect to the design
development of construction projects throughout the Middle East involving healthcare, biotech
other specialty facilities.
Represented WebMD in connection with a $1 billion joint venture with NewsCorp.
Represented WebMD in connection with its joint venture with Japan's Softbank Corp., a to exp
the WebMD technology platform in Japan.
Represented AT&T in connection with an alliance with Microsoft concerning AT & T's Yellow Pages business
use of Yellow Pages as a preferred directory service for Microsoft's online consumer platform.
Represented AT&T as part of a multidisciplinary team in connection with AT & T's strategic alliance with Yahoo! whereby Yahoo!'s online platform
search technology was used to power AT & T's online consumer website, advertising
consumer services platform.
Represented U.S. operator of hospitals in connection with the formation of a Dutch Co-op joint venture with a U.S. multibillion health care company to develop a hospital management business throughout the Middle East.
Represented Blue Cross Blue Shield Association in connection with the strategic development
expansion of its business in China.
For 10 years, served as corporate
transaction counsel to TLC Beatrice International Holdings, a $2 billion annual revenue multinational,
at the time, the largest African American-owned business in the U.S., in transactions including: the $573 million auction sale of its French food distribution
the $190 million auction sale of its ice cream business in Spain
the 146 million sale of its holding companies located in the Netherl
s
the structuring
negotiation of multiple joint ventures, financings
acquisitions in China
the $45 million auction sale of bottling business in the Netherl
s
Belgium to management led buy-out group
the $500 million liquidation of the parent company
distribution of proceeds to the shareholders resulting in a significant return on equity.
Represented Fortune 500 manufacturer of carpets
floor coverings in connection with structuring an implementing joint ventures
commercial relationships with Chinese manufacturers.
Represented NYSE-traded manufacturer Acuity Br
s, Inc. one of the world's leading providers of lighting fixtures
related products
services in connection with its market entry into China
in connection M&A transactions, joint ventures
technology alliances with a strategic alliance with a Chinese
Dubai-based developer of multiple technology providers to develop
exp
its LED lighting technology capability
related service offerings.
Represented UK billionaire investor in connection with the $120 million sale of his casino located in Argentina.
Represented UK billionaire investor in connection with the sale of his Planet Hollywood franchises in Mexico, Chile, Brazil, Argentina
the Cayman Isl
s to a Mexican public company.
Represented a Swedish private equity fund in a $500 million leveraged buyout of a U.S.-based specialty chemical business.
The above representations were h
led by Mr. Elowe prior to his joining Greenberg Traurig, LLP.
